CSL

CSL.AXApproved

Melbourne, AustraliaFounded 1916csl.com

CSL Limited is one of the world's largest biotechnology companies, specializing in plasma-derived therapies, vaccines, and innovative medicines. With a global presence spanning over 35 countries and employing more than 27,000 people, CSL has built a reputation for scientific excellence and operational expertise over more than a century. The company's diversified portfolio includes life-saving treatments for rare diseases, critical care medicines, and seasonal and pandemic vaccines.

Market Cap

$47.0B

Founded

1916

Employees

27,000+

Focus

Biotech

CSL.AX · Stock Price

USD 138.50128.08 (-48.05%)

Historical price data

AI Company Overview

Technology Platform

CSL operates integrated plasma fractionation facilities and vaccine manufacturing platforms, utilizing advanced bioprocessing technologies to develop plasma-derived therapies and cell culture-based vaccines for treating rare diseases and preventing infectious diseases.

Pipeline Snapshot

189

189 drugs in pipeline, 67 in Phase 3

Drug	Indication	Stage
CMVIG	End Stage Renal Disease	Approved
IgPro10	Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Approved
Fibrinogen concentrate + Fresh Frozen Plasma	Coagulopathy in Patients Having Thoraco-Abdominal Aneurysm Repair	Approved
IgPro10	Immune Thrombocytopenic Purpura	Approved
Blood coagulation Factor VIII and vWF, human	Von Willebrand Disease	Approved

FDA Approved Drugs

ANDEMBRYBLAJun 16, 2025

Opportunities

CSL has significant growth opportunities through its late-stage pipeline including CSL112 for cardiovascular disease, expansion into gene therapy with Hemgenix approval, and growing global demand for plasma therapies and pandemic preparedness vaccines.

The company is also well-positioned to benefit from increased plasma collection capacity and expansion into emerging markets.

Risk Factors

Key risks include intense competition from large pharmaceutical companies, regulatory challenges in multiple jurisdictions, dependence on complex plasma supply chains, and potential patent cliff exposure.

The company also faces currency risks from global operations and potential disruption to plasma collection during health crises.

Competitive Landscape

CSL competes with Takeda/Shire, Grifols, and Octapharma in plasma therapeutics, and Sanofi Pasteur and GSK in vaccines. The company differentiates through its vertically integrated plasma collection network, manufacturing excellence, and strong pipeline including the promising cardiovascular candidate CSL112.

Publications

Patents

Pipeline

189

FDA Approvals